Livedo racemosa: A striking dermatological sign for the antiphospholipid syndrome

Journal of Rheumatology

Volumn 33, Issue 12, 2006, Pages 2379-2382

  Uthman, Imad W ^a   Khamashta, Munther A ^b  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; CLINICAL FEATURE; DISEASE COURSE; EDITORIAL; HISTOPATHOLOGY; HUMAN; LIVEDO RACEMOSA; LIVEDO RETICULARIS; PRIORITY JOURNAL; SNEDDON SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIPHOSPHOLIPID SYNDROME; COLD; FEMALE; HUMANS; SKIN; SKIN DISEASES, VASCULAR; SNEDDON SYNDROME; TERMINOLOGY;

EID: 33846137321     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (42)

1. Hughes GR. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. Br Med J (Clin Res Ed) 1983;287:1088-9.
2. Hughes GR. The Prosser-White oration 1983. Connective tissue disease and the skin. Clin Exp Dermatol 1984;9:535-44.
3. Frances C, Niang S, Laffitte E, Pelletier F, Costedoat N, Piette JC. Dermatologic manifestations of the antiphospholipid syndrome: two hundred consecutive cases. Arthritis Rheum 2005;52:1785-93.
4. Asherson RA, Frances C, Iaccarino L, et al. The antiphospholipid antibody syndrome: diagnosis, skin. Clin Exp Rheumatol 2006;24:S46-51.
5. Kraemer M, Linden D, Berlit P. The spectrum of differential diagnosis in neurological patients with livedo reticularis and livedo racemosa. A literature review. J Neurol 2005;252:1155-66.
6. Gibbs MB, English III JC, Zirwas MJ. Livedo reticularis: an update. J Am Acad Dermatol 2005;52:1009-19.
7. Ehrmann S. Ein Gefaessprozess Bei Lues. Wien Med Wochenschr 1907;57:777-82.
8. Lubach D, Schwabe C, Weissenborn K, Hartung K, Creutzig A, Drenk F. Livedo racemosa generalisata: an evaluation of thirty-four cases. J Am Acad Dermatol 1990;22:633-9.
9. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
10. Champion RH, Rook A. Livedo reticularis. Proc R Soc Lond B Biol Sci 1960;53:961-2.
11. Shealy CN, Weeth JB, Mercier D. Livedo reticularis in patients with parkinsonism receiving amantadine. JAMA 1970;212:1522-3.
12. Frances C, Papo T, Wechsler B, Laporte JL, Biousse V, Piette JC. Sneddon syndrome with or without antiphospholipid antibodies. A comparative study in 46 patients. Medicine Baltimore 1999;78:209-19.
13. Sangle S, D'Cruz DP, Hughes GR. Livedo reticularis and pregnancy morbidity in patients negative for antiphospholipid antibodies. Ann Rheum Dis 2005;64:147-8.
14. Sepp N. Other vascular disorders. In: Bolognia J, Jorizzo J, Rapini R, editors. Dermatology. London, New York: Mosby; 2003:1651-9.
15. Hughes GR. Hughes syndrome - the syndrome behind the name (otherwise known as antiphospholipid syndrome). Isr Med Assoc J 1999;1:100-3.
16. Kester S, McCarty DL, McCarty GA. The antiphospholipid antibody syndrome in the emergency department setting - livedo reticularis and recurrent venous thrombosis. Ann Emerg Med 1992;21:207-11.
17. Toubi E. Krause I, Fraser A, et al. Livedo reticularis is a marker for predicting multi-system thrombosis in antiphospholipid syndrome. Clin Exp Rheumatol 2005;23:499-504.
18. Asherson RA, Mayou SC, Merry P, Black MM, Hughes GR. The spectrum of livedo reticularis and anticardiolipin antibodies. Br J Dermatol 1989;120:215-21.
19. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002;46:1019-27.
20. Zelger B, Sepp N, Schmid KW, Hintner H, Klein G, Fritsch PO. Life history of cutaneous vascular lesions in Sneddon's syndrome. Hum Pathol 1992;23:668-75.
21. Wohlrab J, Fischer M, Wolter M, Marsch WC. Diagnostic impact and sensitivity of skin biopsies in Sneddon's syndrome. A report of 15 cases. Br J Dermatol 2001;145:285-8.
22. Sepp N, Zelger B, Schuler G, Romani N, Fritsch P. Sneddon's syndrome - an inflammatory disorder of small arteries followed by smooth muscle proliferation. Immunohistochemical and ultrastructural evidence. Am J Surg Pathol 1995;19:448-53.
23. Englert HJ, Loizou S, Derue GG, Walport MJ, Hughes GR. Clinical and immunologic features of livedo reticularis in lupus: a case-control study. Am J Med 1989;87:408-10.
24. Weinstein C, Miller MH, Axtens R, Buchanan R, Littlejohn GO. Livedo reticularis associated with increased titers of anticardiolipin antibodies in systemic lupus erythematosus. Arch Dermatol 1987;123:596-600.
25. McHugh NJ, Maymo J, Skinner RP, James I, Maddison PJ. Anticardiolipin antibodies, livedo reticularis, and major cerebrovascular and renal disease in systemic lupus erythematosus. Ann Rheum Dis 1988;47:110-5.
26. Baguley E, Asherson RA, Hughes GR. Anticardiolipin antibodies, livedo reticularis, and cerebrovascular accidents in SLE. Ann Rheum Dis 1988;47:702-3.
27. Hughes GR, Khamashta MA. Seronegative antiphospholipid syndrome. Ann Rheum Dis 2003;62:1127.
28. Sangle SR, D'Cruz DP, Jan W, et al. Renal artery stenosis in the antiphospholipid (Hughes) syndrome and hypertension. Ann Rheum Dis 2003;62:999-1002.
29. Sangle SR, D'Cruz DP, Abbs IC, Khamashta MA, Hughes GR. Renal artery stenosis in hypertensive patients with antiphospholipid (Hughes) syndrome: outcome following anticoagulation. Rheumatology Oxford 2005;44:372-7.
30. Piette WW. Antiphospholipid antibody syndrome: the problems and the promise. Br J Dermatol 2000;142:1080-3.
31. Amengual O, Atsumi T, Khamashta MA. Tissue factor in antiphospholipid syndrome: shifting the focus from coagulation to endothelium. Rheumatology Oxford 2003;42:1029-31.
32. Lopez-Pedrera C, Buendia P, Cuadrado MJ, et al. Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappa B/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway. Arthritis Rheum 2006;54:301-11.
33. Karassa FB, Ioannidis JP, Touloumi G, Boki KA, Moutsopoulos HM. Risk factors for central nervous system involvement in systemic lupus erythematosus. Q J Med 2000;93:169-74.
34. West SG, Emlen W, Wener MH, Kotzin BL. Neuropsychiatric lupus erythematosus: a 10-year prospective study on the value of diagnostic tests. Am J Med 1995;99:153-63.
35. Devos J, Bulcke J, Degreef H, Michielsen B. Sneddon's syndrome: generalized livedo reticularis and cerebrovascular disease. Importance of hemostatic screening. Dermatology 1992;185:296-9.
36. Sneddon IB. Cerebro-vascular lesions and livedo reticularis. Br J Dermatol 1965;77:180-5.
37. Frances C, Piette JC. The mystery of Sneddon syndrome: relationship with antiphospholipid syndrome and systemic lupus erythematosus. J Autoimmun 2000;15:139-43.
38. Tietjen GE, Al-Qasmi MM, Shukairy MS. Livedo reticularis and migraine: a marker for stroke risk? Headache 2002;42:352-5.
39. Zelger B, Sepp N, Stockhammer G, et al. Sneddon's syndrome. A long-term follow-up of 21 patients. Arch Dermatol 1993;129:437-47.
40. Levine SR, Langer SL, Albers JW, Welch KM. Sneddon's syndrome: an antiphospholipid antibody syndrome? Neurology 1988;38:798-800.
41. Kalashnikova LA, Nasonov EL, Kushekbaeva AE, Gracheva LA. Anticardiolipin antibodies in Sneddon's syndrome. Neurology 1990;40:464-7.
42. Khamashta MA. Primary prevention of thrombosis in subjects with positive antiphospholipid antibodies. J Autoimmun 2000;15:249-53.